These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 19455969)

  • 21. Photodynamic therapy for polypoidal choroidal vasculopathy.
    Nowak-Sliwinska P; van den Bergh H; Sickenberg M; Koh AH
    Prog Retin Eye Res; 2013 Nov; 37():182-99. PubMed ID: 24140257
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antiangiogenic approaches to age-related macular degeneration today.
    Bressler NM
    Ophthalmology; 2009 Oct; 116(10 Suppl):S15-23. PubMed ID: 19800535
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of two intravitreal ranibizumab treatment schedules for neovascular age-related macular degeneration.
    Gupta B; Adewoyin T; Patel SK; Sivaprasad S
    Br J Ophthalmol; 2011 Mar; 95(3):386-90. PubMed ID: 20693484
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A prospective study on intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration of different durations.
    Algvere PV; Steén B; Seregard S; Kvanta A
    Acta Ophthalmol; 2008 Aug; 86(5):482-9. PubMed ID: 18162062
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Triple therapy for age-related macular degeneration.
    Augustin A
    Retina; 2009 Jun; 29(6 Suppl):S8-11. PubMed ID: 19553805
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ranibizumab versus bevacizumab for the treatment of neovascular age-related macular degeneration.
    Abouammoh M; Sharma S
    Curr Opin Ophthalmol; 2011 May; 22(3):152-8. PubMed ID: 21483262
    [TBL] [Abstract][Full Text] [Related]  

  • 27. One-year follow-up of combined customized therapy. Photodynamic therapy and bevacizumab for exudative age-related macular degeneration.
    Navea A; Mataix J; Desco MC; Garcia-Pous M; Palacios E
    Retina; 2009 Jan; 29(1):13-9. PubMed ID: 18854782
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ranibizumab: new drug. Macular degeneration: second-line use due to risks.
    Prescrire Int; 2008 Feb; 17(93):3-6. PubMed ID: 18354841
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Review of combination therapies for neovascular age-related macular degeneration.
    Couch SM; Bakri SJ
    Semin Ophthalmol; 2011 May; 26(3):114-20. PubMed ID: 21609223
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety of ranibizumab therapy in wet AMD and the role of vascular endothelial growth factors in physiological angiogenesis.
    Figurska M; Robaszkiewicz J; Wierzbowska J
    Klin Oczna; 2010; 112(4-6):147-50. PubMed ID: 20825071
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration.
    Kaiser PK; Blodi BA; Shapiro H; Acharya NR;
    Ophthalmology; 2007 Oct; 114(10):1868-75. PubMed ID: 17628683
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination therapy for age-related macular degeneration.
    Patel S
    Retina; 2009 Jun; 29(6 Suppl):S45-8. PubMed ID: 19553801
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Photodynamic therapy in "Secondary Sick RPE Syndrome" after repeated intravitreal injections of VEGF inhibitors in patients with wet age-related macular degeneration].
    Kloos P; Niederberger H; Valmaggia C
    Klin Monbl Augenheilkd; 2011 Apr; 228(4):340-4. PubMed ID: 21484643
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration.
    Ahmadieh H; Taei R; Soheilian M; Riazi-Esfahani M; Karkhaneh R; Lashay A; Azarmina M; Dehghan MH; Moradian S
    BMC Ophthalmol; 2007 Jun; 7():10. PubMed ID: 17555600
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Age-related macular degeneration (AMD): etiopathogenesis and therapeutic strategies].
    Nowak JZ; Bienias W
    Postepy Hig Med Dosw (Online); 2007; 61():83-94. PubMed ID: 17369776
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New outlook for age-related macular degeneration.
    Covell CA; Graziano JA; Rich D; Tobin KA
    Nursing; 2007 Mar; 37(3):22-4. PubMed ID: 17546779
    [No Abstract]   [Full Text] [Related]  

  • 37. A review of treatments for macular degeneration: a synopsis of currently approved treatments and ongoing clinical trials.
    Liu M; Regillo CD
    Curr Opin Ophthalmol; 2004 Jun; 15(3):221-6. PubMed ID: 15118509
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Emerging biological therapies for the treatment of age-related macular degeneration.
    Asahi MG; Avaylon J; Wallsh J; Gallemore RP
    Expert Opin Emerg Drugs; 2021 Jun; 26(2):193-207. PubMed ID: 34030572
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Treatment guidelines for age-related macular degeneration].
    Takahashi K; Ogura Y; Ishibashi T; Shiraga F; Yuzawa M
    Nippon Ganka Gakkai Zasshi; 2012 Dec; 116(12):1150-5. PubMed ID: 23379205
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Age-related macular degeneration and antivascular endothelial growth factor: a review].
    Fajnkuchen F; Cohen SY
    J Fr Ophtalmol; 2008 Jan; 31(1):94-110. PubMed ID: 18401308
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.